Guardant Health, Inc. $GH Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,541 shares of the company’s stock, valued at approximately $1,345,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. ABS Investment Management LLC acquired a new position in Guardant Health in the second quarter valued at approximately $345,069,000. MCF Advisors LLC increased its stake in Guardant Health by 755.0% in the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after purchasing an additional 151 shares during the last quarter. NFSG Corp purchased a new position in Guardant Health in the third quarter valued at approximately $33,000. Root Financial Partners LLC acquired a new stake in Guardant Health during the third quarter worth approximately $48,000. Finally, TrinityBridge Ltd acquired a new stake in Guardant Health during the second quarter worth approximately $45,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, CTO Darya Chudova sold 7,738 shares of Guardant Health stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer directly owned 70,635 shares of the company’s stock, valued at $12,573,030. The trade was a 9.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Terilyn Monroe sold 46,300 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the sale, the insider owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 163,060 shares of company stock valued at $27,538,217. 5.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, October 15th. The Goldman Sachs Group reiterated a “buy” rating and set a $210.00 price target on shares of Guardant Health in a research note on Friday, July 31st. Morgan Stanley boosted their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, Guggenheim boosted their price target on shares of Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Third-quarter revenue increased 36% year over year to $361 million, above the cited analyst estimate of about $351 million. Oncology revenue rose 25%, while oncology test volumes climbed 58% to 117,000. Guardant also raised its 2026 revenue guidance. Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The reported quarterly loss was $0.29 per share, narrower than the $0.39 loss a year earlier. Guardant Health Reports Q3 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate article suggested GH could be undervalued, while noting a board appointment as a factor investors may consider in assessing the company’s valuation. Guardant Health Could Be 17% Undervalued As Board Appointment Tests Valuation
• Negative Sentiment: The main drag was a higher cash-burn forecast, which raised concerns about spending and the path to profitability despite accelerating sales. Reports said the stock declined following the earnings announcement. Guardant Health Shares Fall as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth

Guardant Health Stock Down 1.7%

NASDAQ:GH opened at $150.87 on Friday. The company has a market capitalization of $20.25 billion, a PE ratio of -41.00 and a beta of 1.67. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05. The stock’s 50 day moving average price is $169.31 and its 200 day moving average price is $132.00.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. Guardant Health’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.74) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.

Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.